Astal Laboratories share price, P/E, ROE & financials

Astal Laboratories (BSE: ASTALLTD) had a P/E of 9.8× on 6 Nov 2026, below the industry P/E of 28.7×, and the shares are 39% below their 52-week high. Its ROCE of 5.5% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. Debt is 0.15× equity. It is a small-cap company with a market cap of ₹265 Cr, ranked 88th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 38% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹60.36
Day high: ₹61.50
Day low: ₹59.50
Prev. close: ₹60.29
Volume: 81.5K

Health check

2 good · 4 to check

ReturnsBehind
−37.8% over a year, better than 0 of 7 peers.
Price tagCheaper
P/E 9.8 vs industry 28.7.
GrowthStrong
Sales +317.7%, profit +863.9% a year over 3 years.
ProfitabilityWeak
ROCE 5.5% vs peer median 17.9%.
Balance sheetStretched
Debt 0.15× equity, interest covered 11.4×, Piotroski 1 of 9.
Red flags2 to check
Return on equity is low at 8.0%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹265 Cr, #88 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹322 Cr · profit ₹22 Cr

Market cap: ₹265 Cr; Small cap
P/E: 9.8; Industry 28.7
Price to book: 4.83; Peers 4.99
Dividend yield: 0.00%
ROE: 8.0%; Peers 14.7%
ROCE: 5.5%; Peers 17.9%
Debt to equity: 0.15; Debt ₹50 Cr
EPS (TTM): ₹6.16
OPM (TTM): 9.4%; Net margin 6.8%
Sales growth: +298.5%; Latest quarter vs a year ago
Profit growth: +350.9%; Latest quarter vs a year ago
Price to sales: 0.82

Strengths

Quarterly profit up 350.9% on a year ago.
Quarterly sales up 298.5% on a year ago.
P/E of 9.8 against an industry P/E of 28.7.

Risks to check

Return on equity is low at 8.0%.
39% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Astal Laboratories

Astal Laboratories Limited manufactures and sells pharmaceutical intermediates and bulk drugs in India. The company was formerly known as Macro International Limited and changed its name to Astal Laboratories Limited in April 2024. Astal Laboratories Limited was incorporated in 1993 and is based in Hyderabad, India.

Headquarters: Hyderabad
Employees: 22
Sector: Healthcare
ISIN: INE307N01014
Website: astallabs.com

Price range

52 weeks

₹49.99₹99.00

Today

₹59.50₹61.50

Avg volume (3M): 19.2K
1-year return: minus 37.8%
From 52-week high: minus 39.0%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
ASTALLTDAstal Laboratories	60.39	plus 0.17%	265	9.8	4.83	5.5%	8.0%	9.4%	317.7%	863.9%	0.00%	minus 37.8%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
25.3	37.5	52.2	40.9	101
22.2	33.6	48.7	38.7	88.7
3.2	3.9	3.6	2.2	12.2
12.5%	10.3%	6.8%	5.4%	12.1%
0.1	0	0	0.1	0.1
0.3	0.3	0.3	0.5	1.2
0.1	0.1	0.1	0.3	0.9
2.8	3.5	3.1	1.5	10.4
25.2%	25.6%	24.7%	26.2%	9.0%
2.1	2.6	2.4	1.1	9.4
1.74	1.97	1.74	0.28	2.18

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +317.7%
Profit CAGR 3Y: +863.9%
EPS CAGR 3Y: +475.2%
ROE: 8.0%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
3.4	23.6	64.2	250
–	+589.8%	+171.6%	+289.5%
3.6	22.5	51.5	230
−0.1	1.1	12.8	20.6
−4.0%	4.7%	19.9%	8.2%
0.2	0	0	−0.1
–	0	0.6	1.7
0	0	0.2	1
−0	–	–	–
0	1.1	12	17.7
48.6%	27.8%	25.5%	17.0%
0	0.8	8.9	14.7
–	+4684.8%	+1037.4%	+64.8%
0.04	1.55	8.04	7.81

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
4	9.8	9.8	42.2
1.2	13.5	26.1	292
–	0.3	13.3	49.9
4.7	13	14.1	135
9.9	36.6	63.3	519
0	0.7	11.4	64.5
–	–	2.1	3.4
0.1	6.1	1.7	0.7
9.8	29.8	48.1	450
9.9	36.6	63.3	519

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
−1.4	−5.6	−12.5	−17.7
1.5	−6.1	−7.8	−2.2
–	17.7	3.3	2.6
0.1	6	−17	−17.3
–	−5.9	−7.8	−2.5
−1.4	−11.5	−20.4	−20.2

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you